RPG Life Sciences Ltd - Stock Valuation and Financial Performance

BSE: 532983 | NSE: RPGLIFE | Pharmaceuticals & Drugs | Small Cap

RPG Life Sciences Share Price

2,312.15 69.60 3.10%
as on 10-Dec'24 16:59

DeciZen - make an informed investing decision on RPG Life Sciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

RPG Life Sciences stock performance -

mw4me loader
P/E Ratio (SA):
54.12
Market Cap:
3,824.1 Cr.
52-wk low:
1,290.3
52-wk high:
2,976.7

Is RPG Life Sciences Ltd an attractive stock to invest in?

1. Is RPG Life Sciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a average quality company.

2. Is RPG Life Sciences Ltd undervalued or overvalued?

The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is RPG Life Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of RPG Life Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
RPG Life Sciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 2.5%9%10.5%12.5%9.8%20.4%27.3%31.5%32.9%35%-
Value Creation
Index
-0.8-0.4-0.3-0.1-0.30.51.01.31.41.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 242279294344330376389440513582618
Sales YoY Gr.-15.3%5.1%17.1%-4%13.8%3.6%13.1%16.5%13.5%-
Adj EPS 0.36.77.486.319.62430.8415342.7
YoY Gr.-2296.4%9.7%9%-21.7%212.4%22.2%28.5%33%29.3%-
BVPS (₹) 75.780.888.993.697.1106.8130.9154.7186226.7229.4
Adj Net
Profit
0.511.112.213.310.432.539.75167.887.771
Cash Flow from Ops. -232.87.314.745.850.258.364.890.894.4-
Debt/CF from Ops. -16.90.76.13.70.80.20000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.2%12%14.4%13.5%
Adj EPS 79.1%53.2%30.3%29.3%
BVPS13%18.5%20.1%21.9%
Share Price 37.8% 51.8% 55.4% 69.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
0.48.68.78.86.619.320.221.624.125.718.7
Op. Profit
Mgn %
3.589.810.810.51618.219.820.322.223.2
Net Profit
Mgn %
0.244.13.93.28.610.211.613.215.111.4
Debt to
Equity
0.30.20.30.40.20.100000
Working Cap
Days
150137123113122105118105979696
Cash Conv.
Cycle
5248494444404440302351

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 14.36%

Net Profit is growing at healthy rate in last 3 years 30.25%

Sales growth is good in last 4 quarters at 12.23%

Return on Equity has declined versus last 3 years average to 18.70%

Latest Financials - RPG Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 42.7 5
TTM Sales (₹ Cr.) 618 121
BVPS (₹.) 229.4 0
Reserves (₹ Cr.) 393 -
P/BV 10.08 0.00
PE 54.12 462.63
From the Market
52 Week Low / High (₹) 1290.30 / 2976.70
All Time Low / High (₹) 17.10 / 2976.70
Market Cap (₹ Cr.) 3,824
Equity (₹ Cr.) 13.2
Face Value (₹) 8
Industry PE 44.2

Management X-Ray of RPG Life Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of RPG Life Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales242279294344330376389440513582
Operating Expenses 234257265307296316318353409453
Manufacturing Costs34383032293340515058
Material Costs778596107104120121128157168
Employee Cost 69747690909195100117132
Other Costs 54606478737262758595
Operating Profit 922293734607187104129
Operating Profit Margin (%) 3.5%8.0%9.8%10.8%10.4%15.9%18.2%19.8%20.2%22.2%
Other Income 7212111357
Interest 3245532111
Depreciation 11101114151616161617
Exceptional Items 00000-50000
Profit Before Tax 11215201536547392118
Tax 00274714222430
Profit After Tax 1121213112940516888
PAT Margin (%) 0.4%4.2%4.1%3.9%3.3%7.7%10.3%11.7%13.2%15.1%
Adjusted EPS (₹)0.67.07.38.16.517.524.231.140.953.0
Dividend Payout Ratio (%)132%23%38%30%37%23%30%31%29%30%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 125134147155161177216256308375
Share Capital 13131313131313131313
Reserves 112120134142147163203243294362
Minority Interest0000000000
Debt332240483671100
Long Term Debt001610721000
Short Term Debt322224382951000
Trade Payables25342952254447466571
Others Liabilities 29332129274038434766
Total Liabilities 212223236284248268303345419512

Fixed Assets

Gross Block176190142151163174180186220222
Accumulated Depreciation71816203551678396108
Net Fixed Assets105109137131128123113104124114
CWIP 1229171012312596
Investments 000000005891
Inventories343946544147588395101
Trade Receivables41373968396357333749
Cash Equivalents 11211141705736
Others Assets31351122222422242225
Total Assets 212223236284248268303345419512

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -233715465058659194
PBT 11223201536547392118
Adjustment 713717202317141313
Changes in Working Capital -611-19-1914-2-4-311-7
Tax Paid -4-2-4-4-4-6-8-19-25-29
Cash Flow From Investing Activity -10-15-30-16-19-11-8-35-106-79
Capex -10-15-55-15-20-11-8-24-33-69
Net Investments 0000000-12-57-27
Others 002500011-1617
Cash Flow From Financing Activity 12-18230-27-39-10-14-17-20
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0020-4-90-4000
Interest Paid -2-2-3-4-4-2-1-100
Dividend Paid -3-40-6-5-130-12-16-20
Others 18-11614-9-25-5-1-10
Net Cash Flow 001-1004017-32-5
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)0.88.988.628.916.8617.2120.3621.824.0125.69
ROCE (%)2.58.9710.4512.529.8120.3527.2731.4632.9234.96
Asset Turnover Ratio1.21.331.341.481.391.591.471.481.451.34
PAT to CFO Conversion(x)-22.750.581.154.181.721.451.271.341.07
Working Capital Days
Receivable Days56494551534553342325
Inventory Days52465047473946545957
Payable Days147127119138135106138133128148

RPG Life Sciences Ltd Stock News

RPG Life Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of RPG Life Sciences on 10-Dec-2024 16:59 is ₹2,312.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Dec-2024 16:59 the market cap of RPG Life Sciences stood at ₹3,824.1.
The latest P/E ratio of RPG Life Sciences as of 10-Dec-2024 16:59 is 54.12.
The latest P/B ratio of RPG Life Sciences as of 10-Dec-2024 16:59 is 10.08.
The 52-week high of RPG Life Sciences is ₹2,976.7 and the 52-week low is ₹1,290.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of RPG Life Sciences is ₹618.3 ( Cr.) .

About RPG Life Sciences Ltd

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.

Achievements:

  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.